Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Issues in the Management of Cancer-Related Thrombocytopenia

November 1, 2002
By William D. Haire, MD
Publication
Article
OncologyONCOLOGY Vol 16 No 11
Volume 16
Issue 11

Cancer-related thrombocytopenia is a clinical problem. Unfortunately, the qualitative nature and quantitative extent of the problem has been poorly defined to date. Without knowing these two parameters, the risk/benefit ratio of any management option for cancer-related thrombocytopenia is impossible to calculate accurately. Drs. Goodnough and DiPersio have done an excellent job of delineating many of the potential risks of managing the problems associated with platelet transfusions.

Cancer-related thrombocytopenia is a clinical problem.Unfortunately, the qualitative nature and quantitative extent of the problem hasbeen poorly defined to date. Without knowing these two parameters, therisk/benefit ratio of any management option for cancer-related thrombocytopeniais impossible to calculate accurately. Drs. Goodnough and DiPersio have done anexcellent job of delineating many of the potential risks of managing theproblems associated with platelet transfusions.

Although transfusion-related viral infections are high on the list ofpotential toxicities, data suggest that, with the exception of cytomegalovirus (CMV),these occur infrequently. Transfusion-related bacterial infections are not oftenconsidered to be a serious clinical problem. However, if one considers that therisk of sepsis with apheresis platelets is 1 in 12,000 and the mortality rateassociated with this sepsis is 26% (as the authors suggest), then patientsreceiving 10 platelet transfusions over the course of their cancer therapy havea 1 in 4,800 risk of death from transfusion. That is not a negligible risk,especially in light of the number of patients who undergo myelosuppressivetreatments for cancer.

Platelet Refractorinessand Other Limitations

Refractoriness to platelet transfusion due to alloimmunization is listed as apotential problem with the use of transfusion therapy, but its clinicalsignificance may be overestimated given the lack of clinical improvement seen inpatients in whom alloimmunization was prevented with the use of leukoreducedplatelets.[1]

The financial expense of platelet transfusion therapy was briefly mentioned,but deserves more detailed consideration. In calculating its expense, the costof all factors associated with the collection of platelets for transfusion(including, for example, time off from work for the platelet donors) should beincluded. These factors are often not accounted for in such analyses.

Another potential downside to platelet transfusions that is not oftenmentioned in this type of review is their potential contribution to thecomplications that occur after administration of chemotherapy. In blood andmarrow transplant patients, increased use of prophylactic platelet transfusionis associated with subsequent development of hepatic veno-occlusive disease,pulmonary dysfunction, and central nervous system (CNS) dysfunction.[2] Althoughthis association does not confirm a causative role for platelet transfusions inthe generation of CNS, pulmonary, or hepatic complications, data from animalmodels and other clinical disorders suggest this possibility.[3-5]

Level of Supportive Evidence

The authors point out that prophylactic platelet transfusion is a commonpractice, but they do not discuss the basis for this practice. Given the actualand potential risks associated with platelet transfusion (CMV infection,bacterial sepsis, cost, alloimmunization, and possibly transplant-related organdysfunction), one would suppose that its prophylactic use in cancer patientswould be based on appropriately designed clinical studies demonstrating improvedclinical outcomes (with prophylactic transfusions vs transfusions to treatbleeding complications). Unfortunately, that is not the case.

As pointed out in another authoritative review, this practice is based onobservational studies (level 4 evidence) of patients treated prior to 1976.[6]Recommendations for the use of prophylactic platelet transfusion in general havebeen based on this level 4 evidence and "expert consensus" rather thanon clinical outcomes of studies in patients treated in contemporary settings.[6]In the studies (cited by the authors) of patient outcomes after prophylacticplatelet transfusions, the only hemorrhagic deaths were in patients whoseplatelet counts exceeded 30,000/µL at the time of death, raising the possibilitythat strategies of prophylactic platelet transfusion based solely on a plateletcount threshold may not eliminate bleeding deaths.

Current recommendations from authoritative sources suggest that the use ofprophylactic platelet transfusion be individualized for specific clinicalsettings and that factors beyond the platelet count be considered in thedecision.[6] The paucity of data supporting the basic concept of prophylacticplatelet transfusions should be kept in mind when discussing the threshold forprophylactic transfusion and the dose of platelets to be administered. Evenlevel 1 evidence and grade A recommendations that "fine tune" the useof an unproven premise are of little clinical value.

Limited Scope

The limited basis for the use of prophylactic platelet transfusion shouldalso be kept in mind when discussing new "pharmacologic options to managecancer-related thrombocytopenia and prevent its attendant morbidity andmortality." As stated by other reviewers, "Fatal hemorrhage is now anunusual event, even in patients with bone marrow failure or in those receivingintensive antineoplastic therapy."[6]

The contribution of thrombocytopenia to the morbidity and mortality of cancerpatients in the contemporary practice of clinical oncology is currently unknown.We cannot assume that improvement of the platelet count, either by transfusionor medication, will improve patient outcome. Indeed, in the only clinical trialof one of the new agents discussed by the authors, patient outcome was no betteramong those who received the active drug than among those who received placebo,save for the platelet count.[7] Hopefully, the history of prophylactic platelettransfusions will not be repeated with these new agents. Before they achievewidespread popularity, they should be shown to produce better clinical outcomesthan placebo, not just a cosmetic improvement in the platelet count.

Conclusions

While it is probably true, as the authors suggest, that "thrombocytopeniaremains a significant clinical problem for patients with cancer" it is alsotrue that the nature and degree of this problem has been poorly defined. Thecurrent therapy for thrombocytopenia—prophylactic platelet transfusion—hasreceived widespread acceptance based on marginal proof of its safety andefficacy. The emergence of new pharmaceuticals designed to replace thetime-honored practice of prophylactic transfusion will provide anotheropportunity to understand the role of platelets in the overall outcome ofpatients with cancer. Hopefully, clinical oncology as a specialty is ready totake advantage of this opportunity.

References:

1. Trial to Reduce Alloimmunization to Platelets Study Group: Leukocytereduction and ultraviolet B irradiation of platelets to prevent alloimmunizationand refractoriness to platelet transfusions. N Engl J Med 337:1861-1869, 1997.

2. Gordon B, Tarantolo S, Ruby E, et al: Increased platelet transfusionrequirement is associated with multiple organ dysfunction in patients undergoinghematopoietic stem cell transplantation. Bone Marrow Transplant 22:999-1003,1998.

3. Heffner J, Sahn S, Repine JE: The role of platelets in adult respiratorydistress syndrome: Culprits or bystanders? Am Rev Respir Dis 135:482-492, 1987.

4. Mannel D, Grau GE: Role of platelet adhesion in homeostasis andimmunopathology. Mol Pathol 50:175-185, 1997.

5. Lou J, Lucas R, Grau GE: Pathogenesis of cerebral malaria: Recentexperimental data and possible applications for humans. Clin Microbiol Rev14:810-820, 2001.

6. Schiffer CA, Anderson KC, Bennet CL, et al: Platelet transfusion forpatients with cancer: Clinical practice gudelines of the American Society ofClinical Oncology. J Clin Oncol 19:1519-1538, 2001.

7. Tepler I, Elias L, Smith JW 2nd, et al: A randomized placebo-controlledtrial of recombinant human interleukin-11 in cancer patients with severethrombocytopenia due to chemotherapy. Blood 87:3607-3614, 1996.

Articles in this issue

Study Reveals Benefits of Drug Pump for Cancer Pain
Three Themes to Guide von Eschenbach as NCI Director
Study Shows Benefits of Adding High-Dose Vitamin D to Chemotherapy for Advanced Prostate Cancer
Update: AIDS United States, 2000
Novel Combination Reduces Tumors Before Surgery in Women With Breast Cancer
New Techniques for Predicting Risk of Breast Cancer and Diagnosing it Early
Rituxan Delays Disease Progression in Indolent Non- Hodgkin’s Lymphoma
Cancer Groups Decry Lack of Key Benefit Enhancements in Senate Medicare Package
Radiation Therapy Alone Can Be Used to Treat Rectal Cancer
Oncologic Imaging, Second Edition
Monitoring Pregnancy Is Key After Wilms’ Treatment
Advances in the Treatment of Gynecologic Malignancies
The Lieberman/Schold Article Reviewed
High-Dose Interleukin-2 in Metastatic Disease: Renal Cell Carcinoma and Melanoma
Issues in the Management of Cancer-Related Thrombocytopenia
Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content
Advertisement

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.

Immunotherapy Rechallenge Exhibits Feasibility in Pretreated ES-SCLC

Roman Fabbricatore
June 27th 2025
Article

Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.


PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.


Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases

Tim Cortese
June 27th 2025
Article

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.


Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Tigilanol Tiglate Exhibits Positive Efficacy in Soft Tissue Sarcoma

Roman Fabbricatore
June 26th 2025
Article

Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Related Content
Advertisement

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.

Immunotherapy Rechallenge Exhibits Feasibility in Pretreated ES-SCLC

Roman Fabbricatore
June 27th 2025
Article

Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.


PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.


Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.

Elraglusib Plus Chemo Improves OS in Metastatic PDAC With Liver Metastases

Tim Cortese
June 27th 2025
Article

Elraglusib plus gemcitabine and nab-paclitaxel demonstrated a median OS of 12.5 months vs 8.5 months with chemotherapy alone in patients with PDAC.


Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Tigilanol Tiglate Exhibits Positive Efficacy in Soft Tissue Sarcoma

Roman Fabbricatore
June 26th 2025
Article

Twenty-two of 27 injected tumors across all patients with soft tissue sarcoma in the study showed complete or partial ablation.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.